Sirolimus: A new immunosuppressant

Journal of Association of Physicians of India

Volumn 53, Issue OCT., 2005, Pages 885-890

  Mukherjee, T ^a   Shah, B V ^b  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

^b LILAVATI HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; REVIEW;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR STRUCTURE; SIROLIMUS;

EID: 26044445068     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Yatscoff RW. Pharmacokinetics of rapamycin. Transplant Proc 1996;28:970-3.
2. Brattstroom C, Tyden G, Shwe J, Herlenius G, Claesson K, Groth CG. A randomised, double-blind, placebo-controlled study to determine safety, tolerance and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant patients. Transplant Proc 1996;28:985-6.
3. Johnson EM, Zimmerman J, Duderstadt K, Chambers J, Sorenson AL, Granger DK, et al. A randomised, double-blind, placebo-controlled study of the safety, tolerance and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 1996;28:987.
4. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997;37:405-15.
5. Trepanier DJ, Gallant H, Legatt DF, Yatscoff RW. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations; an update. Clin Biochem 1998;31:345-51.
6. Yatscoff RW, Aspesket LJ. The monitoring of immunosuppressive drugs: a pharmacodynamic approach. Ther Drug Monit 1998;20:459-63.
7. Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. Correlation between pretransplantation test dose, cyclosporin pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients. Ther Drug Monit 1999;21:44-49.
8. Grimm EM, Kelly PA, Swinford RD, Gitomer JJ, Kahan BD: Sirolimus pharmacokinetics in pediatric renal transplants. Pediatr Transplant 2000;4:S86A.
9. Mathew TH. The safety and efficacy of sirolimus/cyclosporin for the prevention of acute rejection in primary renal allograft recipients. American Society of Transplantation, Abstracts, Chicago, USA, 2000.
10. Kahan BD. Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection: A randomized multicenter study. The Rapamune US Study Group. Lancet 2000;356:194-202.
11. Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother 2001;2:1903-17.
12. Emmanuel Morelon, Marie-France Mamzer-Bruneel, et al. Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrol Dial Transplant 2001;16:18-20.
13. Kahan BD. Two-year Results of Multicenter Phase III Trials on Effect of the Addition of Sirolimus to Cyclosporin-based Immunosuppressive Regimens in Renal Transplantation. Transplant Proc 2003;35:37S-51S.
14. Groth CG, Backman L, Morales J-M, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporin. Transplantation 1999;67:1036-42.
15. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252-60.
16. Kahan BD, Knight R, Schoenberg L, Pobielski J, Kerman RH, Mahalati K, Yakupoglu Y, Aki FT, Katz S, VanBuren CT. Ten years of sirolimus therapy for Human Renal Transplantation: The University of Texas at Houston Experience. Transplant Proc 2003;35:25S-34S.
17. Dumont FJ, Melino MR, Staruch MJ, et al. The immunosuppressive macrolides FK-506 and Rapamycin act as reciprocal antagonists in murine T-cells. J Immunol 1990;144:1418-24.
18. Vivian C McAlister, Zuhua Gao, Kevork Peltekian, Javier Domingues, Karmar Mahalati, AllanS MacDonald. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000;355:376-7.
19. Stegall MD, Larson TS, Prieto M, Gloor J, Textor S, Nyberg S, Sterioff S, Ishitani M, Griffin M, Kremers W, Lund W, Schwab T, Cosio F, Velosa J. Kidney Transplantation without Calcineurin Inhibitors Using Sirolimus. Transplant Proc 2003;35:125S-127S.
20. Hong JC, Kahan BD. Sirolimus rescue therapy for refractory rejection in renal transplantation. Transplantaion 2001;71(11):1579-84.
21. Morelon E, Kreis H. Sirolimus therapy without Calcineurin Inhibitors: Necker Hospital 8-year Experience. Transplant Proc 2003;35:52S-57S.
22. Morales JM, Andres A, Dominiguez-Gil B, Sierra MP, Arenas J, Delgado M, Casal MC, Rodicio L. Tubular Function in Patients with Hypokalemia Induced by Sirolimus after Renal Transplantation. Transplant Proc 2003;35:154S-156S.
23. Christina Brattstrom, Juliette Sawe, Gunnar Tyden, et al. Kinetics and dynamics of single oral doses of sirolimus in 16 renal transplant recipients. Therap Drug Monit 1997;19:397-406.
24. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal transplant patients. N Engl J Med 2000; 343:225-6.
25. Mahalati K, Murphy DM, West ML. Bronchiolitis obliterans and organizing pneumonia in renal transplant recipients. Transplantation 2000;69:1531-2.
26. Steven O Marx, Andrew R Marks. Bench to Bedside. The Development of Rapamycin and Its Application to Stent Restenosis. Circulation 2001;104:852-5.
27. AR Marks. Rapamycin: Signaling in Vascular Smooth Muscle. Transplant Proc 2003;35:231S-233S.
28. Eduardo Sousa J, Marco A Costa, Alexandre Abizaid, Andrea S Abizaid, Fausto Feres, Ibraim MF Pinto, et al. Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries. A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study. Circulation 2001;103:192-5.
29. Sehgal SN. Sirolimus: Its Discovery, Biological Properties, and Mechanism of Action. Transplant Proc 2003;35:7S-14S.